Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Neon Therapeutics Inc (NTGN) Com USD0.001

Sell:$1.48 Buy:$1.49 Change: $0.09 (5.73%)
Market closed |  Prices as at close on 27 February 2020 | Switch to live prices |
Change: $0.09 (5.73%)
Market closed |  Prices as at close on 27 February 2020 | Switch to live prices |
Change: $0.09 (5.73%)
Market closed |  Prices as at close on 27 February 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Neon Therapeutics is a clinical-stage immuno-oncology company. The Company is focused on developing therapeutics leveraging neoantigen biology to treat cancer. The Company's neoantigen-based product engine allows it to develop multiple treatment modalities, including vaccines and thymus (T) cell therapies targeting both personalized and shared neoantigens. The Company's neoantigen-based product engine targets both neoantigens that are specific to individual patients, as well as neoantigens that are shared across patients and tumor types. The Company's NEO-PV-01 program is a personalized neoantigen vaccine. NEO-PV-01 utilizes an epitope computational engine called Real-time Epitope Computation for Oncology (RECON). The Company's NEO-PTC-01 is an Adoptive T Cell Therapy. NEO-PTC-01 uses immunogens in co-culture with T cells and monocyte-derived dendritic cells from patients in order to ex vivo stimulate autologous T cells to respond against neoantigen targets.

Contact details

40 Erie St Ste 110
United States
+1 (617) 3374701

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$42.79 million
Shares in issue:
28.34 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Cary Pfeffer
    Chairman of the Board
  • Hugh Dowd
    President, Chief Executive Officer, Director
  • Yasir Al-Wakeel
    Chief Financial Officer
  • Richard Gaynor
    President Of Research & Development
  • Jolie Siegel
    Vice President, General Counsel, Secretary
  • Kelledy Manson
    Vice President - Product Development
  • Robert Ang
    Chief Business Officer
  • Teresa Regan
    Chief - People And Culture

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.